{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:09:12Z","timestamp":1791806952410,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The YOu and Ulcerative colitis: Registry and Social network (YOURS) is a large-scale, multicenter, patient-focused registry investigating the effects of lifestyle, psychological factors, and clinical practice patterns on patient-reported outcomes in patients with ulcerative colitis in Japan. In this initial cross-sectional baseline analysis, we comprehensively explored impacts of symptom severity or proctocolectomy on nine patient-reported outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients receiving tertiary care at medical institutions were consecutively enrolled in the YOURS registry. The patients completed validated questionnaires on lifestyle, psychosocial factors, and disease-related symptoms. Severity of symptoms was classified with self-graded stool frequency and rectal bleeding scores (categories: remission, active disease [mild, moderate, severe]). The effects of symptom severity or proctocolectomy on nine scales for quality of life, fatigue, anxiety\/depression, work productivity, and sleep were assessed by comparing standardized mean differences of the patient-reported outcome scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 1971 survey responses analyzed, 1346 (68.3%) patients were in remission, 583 (29.6%) had active disease, and 42 (2.1%) had undergone proctocolectomy. A linear relationship between increasing symptom severity and worsening quality of life, fatigue, anxiety, depression, and work productivity was observed. Patients with even mild symptoms had worse scores than patients in remission. Patients who had undergone proctocolectomy also had worse scores than patients in remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ulcerative colitis was associated with reduced mood, quality of life, fatigue, and work productivity even in patients with mild symptoms, suggesting that management of active ulcerative colitis may improve patient-reported outcomes irrespective of disease severity. (UMIN Clinical Trials Registry: UMIN000031995, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.umin.ac.jp\/ctr\/index-j.htm\">https:\/\/www.umin.ac.jp\/ctr\/index-j.htm<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-023-02005-7","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T19:30:42Z","timestamp":1687548642000},"page":"751-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-7660","authenticated-orcid":false,"given":"Katsuyoshi","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Nagahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovelle","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"2005_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","volume":"53","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305\u201353.","journal-title":"J Gastroenterol"},{"key":"2005_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.","journal-title":"Nat Rev Dis Primers"},{"key":"2005_CR3","doi-asserted-by":"publisher","first-page":"9458","DOI":"10.3748\/wjg.v20.i28.9458","volume":"20","author":"BC da Silva","year":"2014","unstructured":"da Silva BC, Lyra AC, Rocha R, et al. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20:9458\u201367.","journal-title":"World J Gastroenterol"},{"key":"2005_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MIB.0000000000001033","volume":"23","author":"S Ghosh","year":"2017","unstructured":"Ghosh S, Louis E, Beaugerie L, et al. Development of the IBD Disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23:333\u201340.","journal-title":"Inflamm Bowel Dis"},{"key":"2005_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","volume":"8","author":"S L\u00f6nnfors","year":"2014","unstructured":"L\u00f6nnfors S, Vermeire S, Greco M, et al. IBD and health-related quality of life\u2014discovering the true impact. J Crohns Colitis. 2014;8:1281\u20136.","journal-title":"J Crohns Colitis"},{"key":"2005_CR6","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/PPA.S175026","volume":"12","author":"X Calvet","year":"2018","unstructured":"Calvet X, Arg\u00fcelles-Arias F, L\u00f3pez-Sanrom\u00e1n A, et al. Patients\u2019 perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain. Patient Prefer Adherence. 2018;12:1815\u201323.","journal-title":"Patient Prefer Adherence"},{"key":"2005_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ecco-jcc\/jjw145","volume":"11","author":"N Williet","year":"2017","unstructured":"Williet N, Sarter H, Gower-Rousseau C, et al. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017;11:165\u201374.","journal-title":"J Crohns Colitis"},{"key":"2005_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1359105312446768","volume":"18","author":"TH Taft","year":"2013","unstructured":"Taft TH, Ballou S, Keefer L. A preliminary evaluation of internalized stigma and stigma resistance in inflammatory bowel disease. J Health Psychol. 2013;18:451\u201360.","journal-title":"J Health Psychol"},{"key":"2005_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12876-020-1164-0","volume":"20","author":"A Armuzzi","year":"2020","unstructured":"Armuzzi A, Tarallo M, Lucas J, et al. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol. 2020;20:18.","journal-title":"BMC Gastroenterol"},{"key":"2005_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/MIB.0000000000000333","volume":"21","author":"PD Jones","year":"2015","unstructured":"Jones PD, Kappelman MD, Martin CF, et al. Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis. 2015;21:1063\u201371.","journal-title":"Inflamm Bowel Dis"},{"key":"2005_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/ajg.2014.247","volume":"110","author":"PJ Parekh","year":"2015","unstructured":"Parekh PJ, Oldfield Iv EC, Challapallisri V, et al. Sleep disorders and inflammatory disease activity: chicken or the egg? Am J Gastroenterol. 2015;110:484\u20138.","journal-title":"Am J Gastroenterol"},{"key":"2005_CR12","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1097\/MIB.0000000000000901","volume":"22","author":"A Tinsley","year":"2016","unstructured":"Tinsley A, Ehrlich OG, Hwang C, et al. Knowledge, attitudes, and beliefs regarding the role of nutrition in IBD among patients and providers. Inflamm Bowel Dis. 2016;22:2474\u201381.","journal-title":"Inflamm Bowel Dis"},{"key":"2005_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cgh.2016.12.036","volume":"15","author":"EL Barnes","year":"2017","unstructured":"Barnes EL, Nestor M, Onyewadume L, et al. High dietary intake of specific fatty acids increases risk of flares in patients with ulcerative colitis in remission during treatment with aminosalicylates. Clin Gastroenterol Hepatol. 2017;15:1390\u20136 (e1).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2005_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ajg.2017.423","volume":"113","author":"B Kochar","year":"2018","unstructured":"Kochar B, Barnes EL, Long MD, et al. Depression is associated with more aggressive inflammatory bowel disease. Am J Gastroenterol. 2018;113:80\u20135.","journal-title":"Am J Gastroenterol"},{"key":"2005_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/ibd\/izy041","volume":"24","author":"V Slonim-Nevo","year":"2018","unstructured":"Slonim-Nevo V, Sarid O, Friger M, et al. Effect of social support on psychological distress and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2018;24:1389\u2013400.","journal-title":"Inflamm Bowel Dis"},{"key":"2005_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030134","volume":"9","author":"H Yamazaki","year":"2019","unstructured":"Yamazaki H, Matsuoka K, Fernandez J, et al. Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: registry and social network). BMJ Open. 2019;9: e030134.","journal-title":"BMJ Open"},{"key":"2005_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3319","volume":"354","author":"EC Nelson","year":"2016","unstructured":"Nelson EC, Dixon-Woods M, Batalden PB, et al. Patient focused registries can improve health, care, and science. BMJ. 2016;354: i3319.","journal-title":"BMJ"},{"key":"2005_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/apt.13408","volume":"42","author":"V Jairath","year":"2015","unstructured":"Jairath V, Khanna R, Zou GY, et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42:1200\u201310.","journal-title":"Aliment Pharmacol Ther"},{"key":"2005_CR19","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"2005_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","volume":"14","author":"A Williamson","year":"2005","unstructured":"Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798\u2013804.","journal-title":"J Clin Nurs"},{"key":"2005_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/0277-9536(91)90150-B","volume":"32","author":"CD Sherbourne","year":"1991","unstructured":"Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705\u201314.","journal-title":"Soc Sci Med"},{"key":"2005_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jclinepi.2012.04.007","volume":"65","author":"A Moser","year":"2012","unstructured":"Moser A, Stuck AE, Silliman RA, et al. The eight-item modified Medical Outcomes Study Social Support Survey: psychometric evaluation showed excellent performance. J Clin Epidemiol. 2012;65:1107\u201316.","journal-title":"J Clin Epidemiol"},{"key":"2005_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2307\/2136404","volume":"24","author":"S Cohen","year":"1983","unstructured":"Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385\u201396.","journal-title":"J Health Soc Behav"},{"key":"2005_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijnurstu.2003.10.009","volume":"41","author":"C Mimura","year":"2004","unstructured":"Mimura C, Griffiths P. A Japanese version of the Perceived Stress Scale: translation and preliminary test. Int J Nurs Stud. 2004;41:379\u201385.","journal-title":"Int J Nurs Stud"},{"key":"2005_CR25","first-page":"1","volume":"49","author":"N Murase","year":"2002","unstructured":"Murase N. Validity and reliability of Japanese version of International Physical Activity Questionnaire. J Health Welfare Stat. 2002;49:1\u20139.","journal-title":"J Health Welfare Stat"},{"key":"2005_CR26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sjostrom M, et al. International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381\u201395.","journal-title":"Med Sci Sports Exerc"},{"key":"2005_CR27","unstructured":"IPAQ Research Committee. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)-short and long forms. 2005. https:\/\/sites.google.com\/site\/theipaq\/scoring-protocol. Accessed Sep 2022"},{"key":"2005_CR28","first-page":"684","volume":"87","author":"GL Brinkman","year":"1963","unstructured":"Brinkman GL, Coates EO Jr. The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis. 1963;87:684\u201393.","journal-title":"Am Rev Respir Dis"},{"key":"2005_CR29","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571\u20138.","journal-title":"Am J Gastroenterol"},{"key":"2005_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1572-0241.2004.04071.x","volume":"99","author":"F Casellas","year":"2004","unstructured":"Casellas F, Alcala MJ, Prieto L, et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004;99:457\u201361.","journal-title":"Am J Gastroenterol"},{"key":"2005_CR31","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1365-2036.2011.04871.x","volume":"34","author":"A Tinsley","year":"2011","unstructured":"Tinsley A, Macklin EA, Korzenik JR, et al. Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:1328\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"2005_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"2005_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/occmed\/kqu024","volume":"64","author":"AF Stern","year":"2014","unstructured":"Stern AF. The Hospital Anxiety and Depression Scale. Occup Med (Lond). 2014;64:393\u20134.","journal-title":"Occup Med (Lond)"},{"key":"2005_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.gastrohep.2018.05.009","volume":"41","author":"JK Yamamoto-Furusho","year":"2018","unstructured":"Yamamoto-Furusho JK, Sarmiento-Aguilar A, Garc\u00eda-Alanis M, et al. Hospital Anxiety and Depression Scale (HADS): validation in Mexican patients with inflammatory bowel disease. Gastroenterol Hepatol. 2018;41:477\u201382.","journal-title":"Gastroenterol Hepatol"},{"key":"2005_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"2005_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193\u2013213.","journal-title":"Psychiatry Res"},{"key":"2005_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0165-1781(00)00232-8","volume":"97","author":"Y Doi","year":"2000","unstructured":"Doi Y, Minowa M, Uchiyama M, et al. Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res. 2000;97:165\u201372.","journal-title":"Psychiatry Res"},{"key":"2005_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/00365521.2019.1602669","volume":"54","author":"S Saraiva","year":"2019","unstructured":"Saraiva S, Cortez-Pinto J, Barosa R, et al. Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice. Scand J Gastroenterol. 2019;54:465\u201370.","journal-title":"Scand J Gastroenterol"},{"key":"2005_CR39","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: L. Erlbaum Associates; 1988.","edition":"2"},{"key":"2005_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/codi.15301","volume":"23","author":"DM Baker","year":"2021","unstructured":"Baker DM, Folan AM, Lee MJ, et al. A systematic review and meta-analysis of outcomes after elective surgery for ulcerative colitis. Colorectal Dis. 2021;23:18\u201333.","journal-title":"Colorectal Dis"},{"key":"2005_CR41","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2020.1801187","volume":"23","author":"E Walter","year":"2020","unstructured":"Walter E, Hausberger SC, Gross E, et al. Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. J Med Econ. 2020;23:1061\u201371.","journal-title":"J Med Econ"},{"key":"2005_CR42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5009\/gnl19107","volume":"14","author":"JR Moon","year":"2020","unstructured":"Moon JR, Lee CK, Hong SN, et al. Unmet psychosocial needs of patients with newly diagnosed ulcerative colitis: results from the nationwide prospective cohort study in Korea. Gut Liver. 2020;14:459\u201367.","journal-title":"Gut Liver"},{"key":"2005_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181435","volume":"12","author":"A Villoria","year":"2017","unstructured":"Villoria A, Garcia V, Dosal A, et al. Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors. PLoS\u00a0One. 2017;12:e0181435.","journal-title":"PLoS&nbsp;One"},{"key":"2005_CR44","volume":"4","author":"D Farrell","year":"2020","unstructured":"Farrell D, Artom M, Czuber-Dochan W, et al. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev. 2020;4: CD012005.","journal-title":"Cochrane Database Syst Rev"},{"key":"2005_CR45","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324\u201338.","journal-title":"Am J Gastroenterol"},{"key":"2005_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1572-0241.2000.01676.x","volume":"95","author":"SW Han","year":"2000","unstructured":"Han SW, Gregory W, Nylander D, et al. The SIBDQ: further validation in ulcerative colitis patients. Am J Gastroenterol. 2000;95:145\u201351.","journal-title":"Am J Gastroenterol"},{"key":"2005_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","volume":"61","author":"L Peyrin-Biroulet","year":"2012","unstructured":"Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241\u20137.","journal-title":"Gut"},{"key":"2005_CR48","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/ecco-jcc\/jjaa100","volume":"14","author":"C Le Berre","year":"2020","unstructured":"Le Berre C, Flamant M, Bouguen G, et al. VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases in a French cohort: the VALIDate study. J Crohns Colitis. 2020;14:1512\u201323.","journal-title":"J Crohns Colitis"},{"key":"2005_CR49","doi-asserted-by":"publisher","first-page":"2065383","DOI":"10.1155\/2020\/2065383","volume":"2020","author":"S Dragasevic","year":"2020","unstructured":"Dragasevic S, Sokic-Milutinovic A, Stojkovic Lalosevic M, et al. Correlation of patient-reported outcome (PRO-2) with endoscopic and histological features in ulcerative colitis and Crohn\u2019s disease patients. Gastroenterol Res Pract. 2020;2020:2065383.","journal-title":"Gastroenterol Res Pract"}],"updated-by":[{"DOI":"10.1007\/s00535-024-02116-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000}}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02005-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T16:04:47Z","timestamp":1717085087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02005-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02005-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00535-024-02116-9","asserted-by":"object"}]},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00535-024-02116-9","URL":"https:\/\/doi.org\/10.1007\/s00535-024-02116-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katsuyoshi Matsuoka has received honoraria and research grants from AbbVie, EA Pharma, Pfizer, Mochida, Kyorin, ZERIA, Kissei, Nippon Kayaku, JIMRO, and honoraria from Mitsubishi Tanabe, Takeda, Janssen, MIYARISAN and Celltrion Healthcare. Hajime Yamazaki has received an\u00a0honorarium from Takeda. Masakazu Nagahori has received honoraria from Mitsubishi Tanabe, Janssen, Kyorin, AbbVie, and research grants from Takeda, Pfizer and Eli Lilly. Taku Kobayashi has received honoraria and research grants from Takeda, Activaid, Alfresa, ZERIA, Kyorin, Nippon Kayaku, Mitsubishi Tanabe, AbbVie, Pfizer, Janssen, JIMRO, EA Pharma, Mochida, Bristol-Myers Squibb, Eli Lilly, honoraria from Thermo Fisher diagnostics, Galapagos, Kissei, and research grants from JMDC, Gilead Sciences, Otsuka and Google Asia Pacific. Teppei Omori has received an\u00a0honorarium from Takeda. Toshimitsu Fujii has received honoraria and research grants from AbbVie, EA Pharma, Janssen, Kissei, Nichiiko, Takeda, ZERIA, honoraria from Daiichi Sankyo, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, and research grants from Alfresa, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly and Gilead Sciences. Shinichiro Shinzaki has received honoraria from AbbVie, Alfresa, AstraZeneca, EA Pharma, Eisai, Gilead Sciences, Kissei, Kyorin, Janssen, JIMRO, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer, Sekisui Medical, Takeda, ZERIA, and a research grant from Sekisui Medical. Masayuki Saruta has received honoraria and scholarship grants from AbbVie, EA Pharma, ZERIA, Kissei, Mochida, and honoraria from Janssen, Mitsubishi Tanabe, Pfizer, Gilead Sciences and Takeda. Minoru Matsuura has received honoraria from Mitsubishi Tanabe, AbbVie, Takeda, Janssen, Kyorin, Mochida, Viatris, Nippon Kayaku, EA Pharma, JIMRO, ZERIA and Aspen. Toshifumi Hibi has received honoraria and research grants from AbbVie, Mitsubishi Tanabe, Mochida, Takeda, ZERIA, Kyorin, JIMRO, honoraria from Sandoz, Gilead Sciences, Janssen, Pfizer, EA Pharma, APO PLUS STATION, Bristol-Myers Squibb, Eli Lilly, Nichi-Iko, and research grants from Otsuka, Alfresa and MIYARISAN. Mamoru Watanabe has received honoraria and research grants from EA Pharma, Mitsubishi Tanabe, Takeda, ZERIA, Kissei, Mochida, AbbVie, honoraria from Pfizer, Boehringer Ingelheim, Gilead Sciences, Janssen, Celltrion Healthcare, JIMRO, Eli Lilly, and research grants from Nippon Kayaku, Kyorin and Alfresa. Jovelle Fernandez was an employee of Takeda when the study was conducted and owns restricted stocks of Takeda and GlaxoSmithKline. Shunichi Fukuhara has received an\u00a0honorarium from Takeda. Tadakazu Hisamatsu has received honoraria from EA Pharma, AbbVie, Celgene, Janssen, Pfizer, Nichi-Iko, Mitsubishi Tanabe, AbbVie, Kyorin, JIMRO, Mochida, Takeda, research grants from Alfresa and EA Pharma, and scholarship grants from Mitsubishi Tanabe, EA Pharma, AbbVie, JIMRO, ZERIA, Daiichi Sankyo, Kyorin, Nippon Kayaku, Takeda, Pfizer and Mochida. Yohei Mikami, Takayuki Yamamoto, and Satoshi Motoya declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}